['\xe2\x86\x91\xc2\xa0\xc2\xa0INDICATES INCREASE.', '\xe2\x86\x93\xc2\xa0\xc2\xa0INDICATES DECREASE.', 'A THE DOSING RECOMMENDATION FOR COADMINISTRATION OF VIDEX EC AND TENOFOVIR DISOPROXIL FUMARATE WITH RESPECT TO MEAL CONSUMPTION DIFFERS FROM THAT OF VIDEX. SEE THE COMPLETE PRESCRIBING INFORMATION FOR VIDEX EC.', 'CIPROFLOXACIN', '\xe2\x86\x93\xc2\xa0CIPROFLOXACIN CONCENTRATION', 'ADMINISTER VIDEX AT LEAST 2 HOURS AFTER OR 6 HOURS BEFORE CIPROFLOXACIN.', 'DELAVIRDINE', '\xe2\x86\x93\xc2\xa0DELAVIRDINE CONCENTRATION', 'ADMINISTER VIDEX 1 HOUR AFTER DELAVIRDINE.', 'GANCICLOVIR', '\xe2\x86\x91\xc2\xa0DIDANOSINE CONCENTRATION', 'IF THERE IS NO SUITABLE ALTERNATIVE TO GANCICLOVIR, THEN USE IN COMBINATION WITH VIDEX WITH CAUTION. MONITOR FOR DIDANOSINE-ASSOCIATED TOXICITY.', 'INDINAVIR', '\xe2\x86\x93\xc2\xa0INDINAVIR CONCENTRATION', 'ADMINISTER VIDEX 1 HOUR AFTER INDINAVIR.', 'METHADONE', '\xe2\x86\x93\xc2\xa0DIDANOSINE CONCENTRATION', 'DO NOT COADMINISTER METHADONE WITH VIDEX PEDIATRIC POWDER DUE TO SIGNIFICANT DECREASES IN DIDANOSINE CONCENTRATIONS. IF COADMINISTRATION OF METHADONE AND DIDANOSINE IS NECESSARY, THE RECOMMENDED FORMULATION OF DIDANOSINE IS VIDEX EC. PATIENTS SHOULD BE CLOSELY MONITORED FOR ADEQUATE CLINICAL RESPONSE WHEN VIDEX EC IS COADMINISTERED WITH METHADONE, INCLUDING MONITORING FOR CHANGES IN HIV RNA VIRAL LOAD.', 'NELFINAVIR', 'NO INTERACTION 1 HOUR AFTER DIDANOSINE', 'ADMINISTER NELFINAVIR 1 HOUR AFTER VIDEX.', 'TENOFOVIR DISOPROXIL FUMARATE', '\xe2\x86\x91\xc2\xa0DIDANOSINE CONCENTRATION', 'A DOSE REDUCTION OF VIDEX TO THE FOLLOWING DOSAGE ONCE DAILY IS RECOMMENDED. A 250 MG (ADULTS WEIGHING AT LEAST 60 KG WITH CREATININE CLEARANCE OF AT LEAST 60 ML/MIN) 200 MG (ADULTS WEIGHING LESS THAN 60 KG WITH CREATININE CLEARANCE OF AT LEAST 60\xc2\xa0ML/MIN) VIDEX AND TENOFOVIR DISOPROXIL FUMARATE MAY BE TAKEN TOGETHER IN THE FASTED STATE. IF TENOFOVIR DISOPROXIL FUMARATE IS TAKEN WITH FOOD, VIDEX SHOULD BE TAKEN ON AN EMPTY STOMACH (AT LEAST 30\xc2\xa0MINUTES BEFORE FOOD OR 2\xc2\xa0HOURS AFTER FOOD). PATIENTS SHOULD BE MONITORED FOR DIDANOSINE-ASSOCIATED TOXICITIES AND CLINICAL RESPONSE.']